UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 18, 2018
AVEO Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-34655 | 04-3581650 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| One Broadway, 14th Floor Cambridge, Massachusetts |
02142 | |||
| (Address of Principal Executive Offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (617) 588-1960
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
On June 18, 2018, AVEO Pharmaceuticals, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the following proposals:
1. The following nominees were elected to the Company’s Board of Directors for terms expiring at the 2019 annual meeting of stockholders.
| For | Withheld | Broker Non- Votes |
||||||||||
| Mr. Michael P. Bailey |
49,464,917 | 305,265 | 49,543,430 | |||||||||
| Mr. Kenneth M. Bate |
47,837,807 | 1,932,375 | 49,543,430 | |||||||||
| Dr. Anthony B. Evnin |
49,459,199 | 310,983 | 49,543,430 | |||||||||
| Mr. John H. Johnson |
48,179,436 | 1,590,746 | 49,543,430 | |||||||||
| Dr. Robert C. Young |
49,366,496 | 403,686 | 49,543,430 | |||||||||
2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.
| For: |
48,704,579 | |||
| Against: |
783,037 | |||
| Abstain: |
282,566 | |||
| Broker Non-Votes: |
49,543,430 |
3. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2018 was ratified.
| For: |
98,604,832 | |||
| Against: |
498,600 | |||
| Abstain: |
210,180 | |||
| Broker Non-Votes: |
0 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AVEO Pharmaceuticals, Inc. | ||||||
| By: | /s/ Matthew Dallas | |||||
| Matthew Dallas | ||||||
| Chief Financial Officer | ||||||
| Date: June 21, 2018 | ||||||